30
total announcements
SMSPHARMA.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹4,071 Cr
P/E (TTM)
38.7
EPS (TTM)
₹11.24
52W Low
₹270.10
52W High
₹494.45
Dividend Yield
0.09%
Beta
0.28
Price / Book
5.2
Debt / Equity
46.5
Revenue (TTM)
₹898 Cr
Gross Margin
34.64%
Operating Margin
14.96%
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter and half year ended 30th September, 2026, confirming compliance with Regulation 74(5) regarding dematerialization of securities.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has submitted the Exchange a copy Scrutinizers report of Annual General Meeting held on September 29, 2026, and informed the Exchange regarding voting results.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 29, 2026. The 38th Annual General Meeting of the Company was held through video conference in compliance with circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India (SEBI) and other applicable provisions of the Companies Act, 2013.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has informed the Exchange regarding the closure of its Trading Window pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, from 01st October, 2026 till 48 hours after the declaration of financial results for the Second quarter and half year ended 30th September, 2026.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has informed the Exchange about the schedule of an analyst/institutional investor meeting on September 15, 2026, in Hyderabad.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has informed the Exchange about the dispatch of the Notice of the 38th Annual General Meeting (AGM) and Integrated Annual Report for the financial year 2025-2026.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has informed the Exchange regarding 'Letter to Shareholders regarding Annual Report'. The company has dispatched a letter providing web-link and QR code to Annual Report for FY 2025-26 to shareholders whose e-mail addresses are not registered with the Company/Registrar & Share Transfer Agent/Depositories. The company has also announced the 38th Annual General Meeting (AGM) of SMS Pharmaceuticals Limited, scheduled to be held on 29th September, 2026, through Video Conference (VC) / Other Audio-Visual Means (OAVM).
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 29, 2026.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has informed the Exchange about Credit Rating. CARE Ratings Limited has reaffirmed/revised its ratings assigned to the bank facilities of the Company.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has informed the Exchange about the submission of copies of Newspaper Publication regarding the 38th Annual General Meeting to be held through Video Conference/ Other Audio Visual Means.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has revised the record date for determining the members eligible to receive the dividend for the financial year 2025-26 to 22nd September 2026 from 16th September 2026.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has informed the Exchange about change in date of 38th Annual General Meeting due to unavoidable circumstances and administrative constraints.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has informed the Exchange about the submission of copies of newspaper publication regarding the 38th Annual General Meeting to be held through Video Conference/Other Audio Visual Means. The advertisement has been published in the Financial Express and Nava Telangana newspapers, and is also available on the company's website.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has informed the Exchange regarding the tax deduction at source on dividend for the financial year 2025-26, subject to shareholder approval at the 38th Annual General Meeting.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has announced the publication of its audited standalone and consolidated financial results for the first quarter ended June 30, 2026, in accordance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has informed the Exchange about Investor Presentation, which includes Q1FY27 financial highlights and key operating metrics. The company's revenue up 6% YoY, driven by diversified growth across high-value APIs, with gross margin remaining above 45% and EBITDA margin sustained at ~20%. The company has completed 4 DMF/CEP filings and is on track to meet FY27 target of 10 DMF/CEP filings. A ₹280 crore capex programme is progressing as planned, and the board has approved infusion of up to ₹50 crore, as a loan, into subsidiary SMS Peptides Private Limited.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue up 6% YoY, driven by diversified growth across high-value APIs, gross margin above 45%, and EBITDA margin sustained at ~20%. The company has completed 4 DMF/CEP filings and is on track to meet its FY27 target of 10 filings. The ₹280 crore capex programme is progressing as planned, and the company has approved the infusion of up to ₹50 crore as a loan into its subsidiary SMS Pepdes Private Limited.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has announced its financial results for the first quarter ended 30th June, 2026, along with the re-appointment of its Managing Director, Mr. Ramesh Babu Potluri, and the approval to give a loan to its subsidiary, SMS Peptides Private Limited.
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited has announced its record date for the purpose of dividend as 16-Sep-2026. The company has also approved its standalone and consolidated un-audited financial results for the first quarter ended 30th June, 2026, and has fixed the record date for the 38th Annual General Meeting (AGM) as 16th September, 2026.